Pharmacist-led rapid point-of-care CYP2C19 genotyping for individualisation of antiplatelet therapy

Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/49976

Title:	Pharmacist-led rapid point-of-care CYP2C19 genotyping for individualisation of antiplatelet therapy
Authors:	Wirth, Francesca Xuereb, Robert G. Fenech, Albert Azzopardi, Lilian M.
Keywords:	Blood platelet disorders Blood platelets -- Aggregation Clopidogrel Coronary arteries -- Stenosis Point-of-care testing Cytochrome P-450 CYP2C19 Pharmacists -- Practice
Issue Date:	2016-03
Publisher:	University of Malta. Department of Pharmacy
Citation:	Wirth, F., Xuereb, R. G., Fenech, A., & Azzopardi, L. M. (2016, March). Pharmacist-led rapid point-of-care CYP2C19 genotyping for individualisation of antiplatelet therapy. Poster session presented at the 21st Congress of the European Association of Hospital Pharmacists, Vienna, Austria.
Abstract:	A poster presentation regarding pharmacist-led rapid point-of-care CYP2C19 genotyping for individualisation of antiplatelet therapy. Background: Presence of the CYP2C19 loss-of-function (LoF) 2 allele is associated with reduced antiplatelet effect in clopidogrel-treated patients. Since about 50% of major adverse cardiac events occur within the first few days after percutaneous coronary intervention (PCI), a rapid CYP2C192 genotype result is important to individualise antiplatelet therapy at the start of treatment. Objective: To apply a pharmacist-led process to individualise antiplatelet therapy guided by CYP2C19*2 genotype using the novel rapid point-of-care (POC) genetic testing system in patients undergoing PCI.
URI:	https://www.um.edu.mt/library/oar/handle/123456789/49976
Appears in Collections:	Scholarly Works - FacM&SPha

Files in This Item:

File	Description	Size	Format
Pharmacist_led_rapid_point_of_care_CYP2C19_genotyping_for_individualisation_of_antiplatelet_therapy_2016.pdf		383.35 kB	Adobe PDF	View/Open

Show full item record Statistics